Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · IEX Real-Time Price · USD
14.71
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
15.10
+0.39 (2.65%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Tourmaline Bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Tourmaline Bio stock have an average target of 61.8, with a low estimate of 48 and a high estimate of 74. The average target predicts an increase of 320.12% from the current stock price of 14.71.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 14, 2024.
Analyst Ratings
The average analyst rating for Tourmaline Bio stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $48 | Strong Buy | Reiterates | $48 | +226.31% | May 14, 2024 |
Truist Securities | Truist Securities | Strong Buy Reiterates $74 | Strong Buy | Reiterates | $74 | +403.06% | Mar 25, 2024 |
Jefferies | Jefferies | Strong Buy Maintains $41 → $72 | Strong Buy | Maintains | $41 → $72 | +389.46% | Mar 20, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $48 | Strong Buy | Reiterates | $48 | +226.31% | Mar 20, 2024 |
Jefferies | Jefferies | Strong Buy Initiates $41 | Strong Buy | Initiates | $41 | +178.72% | Dec 15, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
12.24M
EPS This Year
-2.98
from -8.87
EPS Next Year
-3.25
from -2.98
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | 63.0M | 63.0M | 63.0M | 213.6M |
Avg | n/a | 12.2M | 12.2M | 18.9M | 112.8M |
Low | n/a | n/a | n/a | n/a | 26.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | 414.7% | 414.7% | 1,028.1% |
Avg | - | - | - | 54.7% | 496.0% |
Low | - | - | - | - | 39.8% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -2.53 | -1.28 | -2.58 | -3.70 | -0.16 |
Avg | -2.98 | -3.25 | -3.78 | -4.42 | -1.82 |
Low | -3.79 | -4.54 | -4.62 | -4.75 | -3.08 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.